Inovio Pharmaceuticals, Inc. (INO) Rating Reiterated by Stifel Nicolaus

Xavier Trudeau
Juin 14, 2017

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) share price decreased in the last trading session with a previous 52-week high of $11.61. (NASDAQ:INO) stock have an ABR of 1.40. They now have a Dollars 14 price target on the stock. Brean Capital maintained the stock with "Buy" rating in Monday, March 14 report. The firm earned "Neutral" rating on Thursday, March 16 by PiperJaffray. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the company.

05/24/2017 - Inovio Pharmaceuticals, Inc. had its " rating reiterated by analysts at Maxim Group. "Ultimately, through all this investigation into the company's performance the analyst decides if their stock is a "buy", sell" or hold". The company has an average rating of Buy and a consensus price target of $19.57. Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Wednesday, May 10th. AlphaOne also assigned media coverage about the biopharmaceutical company an impact score of 75 out of 100, meaning that recent media coverage is likely to have an impact on the company's share price in the next several days. The company has market cap of $616.48 million.

Presently Inovio Pharmaceuticals, Inc. Looking ahead to earnings forecasts, for the running fiscal period, Wall Street analysts have anticipated that the company will report -0.19 earnings per share. Inovio Pharmaceuticals had a negative return on equity of 65.97% and a negative net margin of 235.91%. The business's quarterly revenue was up 28.4% compared to the same quarter a year ago. During the same period a year ago, the company posted ($0.11) earnings per share. Relative Strength Index (RSI-14) for Inovio Pharmaceuticals, Inc.

05/24/2017 - Inovio Pharmaceuticals, Inc. had its " rating reiterated by analysts at Stifel Nicolaus. American International Group Inc. now owns 40,856 shares of the biopharmaceutical company's stock valued at $270,000 after buying an additional 2,695 shares in the last quarter. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and worldwide trademark & copyright law.

Let's have a look at some of the important valuation ratios of the Inovio Pharmaceuticals, Inc. The short sellers will then buy the stock back at a much lower price and replace the borrowed shares, pocketing the difference. The high and low revenue estimates for the current quarter are $32.29 Million and $5.2 Million, respectively. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The legal version of this piece of content can be read at https://sportsperspectives.com/2017/06/12/inovio-pharmaceuticals-inc-ino-given-a-12-00-price-target-by-maxim-group-analysts.html. Stoneridge Investment Partners LLC now owns 254,449 shares of the biopharmaceutical company's stock valued at $1,684,000 after buying an additional 2,073 shares in the last quarter.

D'autres rapports CampDesrEcrues

Discuter de cet article

SUIVRE NOTRE JOURNAL